-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明，無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Imago BioSciences (NASDAQ:IMGO) Trading Down 7%
Imago BioSciences (NASDAQ:IMGO) Trading Down 7%
Shares of Imago BioSciences, Inc. (NASDAQ:IMGO – Get Rating) traded down 7% during mid-day trading on Monday . The stock traded as low as $17.04 and last traded at $17.11. 846 shares were traded during trading, a decline of 100% from the average session volume of 204,228 shares. The stock had previously closed at $18.39.
Analyst Upgrades and Downgrades
Separately, HC Wainwright dropped their price objective on Imago BioSciences from $36.00 to $35.00 and set a "buy" rating on the stock in a report on Tuesday, August 16th.
Get Imago BioSciences alerts:Imago BioSciences Trading Up 5.2 %
The firm has a fifty day simple moving average of $15.66 and a 200-day simple moving average of $17.66.
Insider Activity
In other news, insider Jennifer Peppe sold 5,598 shares of the business's stock in a transaction that occurred on Monday, August 15th. The stock was sold at an average price of $19.41, for a total value of $108,657.18. Following the completion of the sale, the insider now directly owns 148,809 shares in the company, valued at approximately $2,888,382.69. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In the last ninety days, insiders sold 7,721 shares of company stock worth $147,356. 14.90% of the stock is currently owned by insiders.Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in IMGO. Allspring Global Investments Holdings LLC acquired a new position in Imago BioSciences during the 4th quarter valued at approximately $94,000. New York State Common Retirement Fund acquired a new position in Imago BioSciences during the 4th quarter valued at approximately $154,000. Northern Trust Corp boosted its position in Imago BioSciences by 25.0% during the 4th quarter. Northern Trust Corp now owns 107,122 shares of the company's stock valued at $2,541,000 after purchasing an additional 21,413 shares during the period. Swiss National Bank acquired a new position in Imago BioSciences during the 4th quarter valued at approximately $612,000. Finally, Alps Advisors Inc. acquired a new position in Imago BioSciences during the 4th quarter valued at approximately $920,000. Institutional investors and hedge funds own 88.28% of the company's stock.
About Imago BioSciences
(Get Rating)
Imago BioSciences, Inc, a clinical stage biopharmaceutical company, discovers and develops small molecule product candidates that target lysine-specific demethylase 1(LSD1), an enzyme that used in the production of blood cells in the bone marrow. Its lead product candidate is bomedemstat, which is in Phase II clinical trials for the treatment of myeloproliferative neoplasms chronic cancers of the bone marrow, such as myelofibrosis, essential thrombocythemia, and polycythemia vera.
See Also
- Get a free copy of the StockNews.com research report on Imago BioSciences (IMGO)
- Will the Real Palantir Please Stand Up?
- Foot Locker Just Because A Very Tempting Buy
- Are Ocugen or Amarin Good Penny Stocks to Buy?
- Are These 2 Fintechs A Buy After Q2 Earnings?
- Chipotle is Cooking Up Another Run at $2,000
Receive News & Ratings for Imago BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imago BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.
Shares of Imago BioSciences, Inc. (NASDAQ:IMGO – Get Rating) traded down 7% during mid-day trading on Monday . The stock traded as low as $17.04 and last traded at $17.11. 846 shares were traded during trading, a decline of 100% from the average session volume of 204,228 shares. The stock had previously closed at $18.39.
週一午盤，Imago BioSciences，Inc.(納斯達克代碼：IMGO-GET Rating)的股價下跌了7%。該股最低交易價格為17.04美元，最後報17.11美元。當日成交量為846股，較204,228股的平均日成交量下降100%。該股此前收盤價為18.39美元。
Analyst Upgrades and Downgrades
分析師升級和下調評級
Separately, HC Wainwright dropped their price objective on Imago BioSciences from $36.00 to $35.00 and set a "buy" rating on the stock in a report on Tuesday, August 16th.
另外，在8月16日星期二的一份報告中，HC Wainwright將Imago BioSciences的目標價從36.00美元下調至35.00美元，並對該股設定了買入評級。
Imago BioSciences Trading Up 5.2 %
Imago BioSciences股價上漲5.2%
The firm has a fifty day simple moving average of $15.66 and a 200-day simple moving average of $17.66.
該公司的50日簡單移動均線為15.66美元，200日簡單移動均線為17.66美元。
Insider Activity
內幕活動
Institutional Inflows and Outflows
機構資金流入和流出
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in IMGO. Allspring Global Investments Holdings LLC acquired a new position in Imago BioSciences during the 4th quarter valued at approximately $94,000. New York State Common Retirement Fund acquired a new position in Imago BioSciences during the 4th quarter valued at approximately $154,000. Northern Trust Corp boosted its position in Imago BioSciences by 25.0% during the 4th quarter. Northern Trust Corp now owns 107,122 shares of the company's stock valued at $2,541,000 after purchasing an additional 21,413 shares during the period. Swiss National Bank acquired a new position in Imago BioSciences during the 4th quarter valued at approximately $612,000. Finally, Alps Advisors Inc. acquired a new position in Imago BioSciences during the 4th quarter valued at approximately $920,000. Institutional investors and hedge funds own 88.28% of the company's stock.
一些對衝基金和其他機構投資者最近增持或減持了IMGO的股份。AllSpring Global Investments Holdings LLC在第四季度收購了Imago BioSciences的一個新頭寸，價值約為9.4萬美元。紐約州共同退休基金在第四季度收購了Imago BioSciences的一個新頭寸，價值約為154,000美元。北方信託公司在第四季度將其在Imago BioSciences的地位提高了25.0%。北方信託公司目前持有107,122股該公司股票，價值2,541,000美元，在此期間又購買了21,413股。瑞士國家銀行在第四季度收購了Imago BioSciences的一個新頭寸，價值約為61.2萬美元。最後，Alps Advisors Inc.在第四季度收購了Imago BioSciences的一個新頭寸，價值約為92萬美元。機構投資者和對衝基金持有該公司88.28%的股票。
About Imago BioSciences
關於Imago BioSciences
(Get Rating)
(獲取評級)
Imago BioSciences, Inc, a clinical stage biopharmaceutical company, discovers and develops small molecule product candidates that target lysine-specific demethylase 1(LSD1), an enzyme that used in the production of blood cells in the bone marrow. Its lead product candidate is bomedemstat, which is in Phase II clinical trials for the treatment of myeloproliferative neoplasms chronic cancers of the bone marrow, such as myelofibrosis, essential thrombocythemia, and polycythemia vera.
臨牀階段生物製藥公司Imago BioSciences，Inc.發現和開發了針對賴氨酸特異性脱甲基酶1(LSD1)的小分子產品候選產品，LSD1是一種用於生產骨髓中血細胞的酶。它的主要候選產品是Bomedemstat，正在進行第二階段臨牀試驗，用於治療骨髓增生性腫瘤和慢性骨髓癌，如骨髓纖維化、原發性血小板增多症和真性紅細胞增多症。
See Also
另請參閲
- Get a free copy of the StockNews.com research report on Imago BioSciences (IMGO)
- Will the Real Palantir Please Stand Up?
- Foot Locker Just Because A Very Tempting Buy
- Are Ocugen or Amarin Good Penny Stocks to Buy?
- Are These 2 Fintechs A Buy After Q2 Earnings?
- Chipotle is Cooking Up Another Run at $2,000
- 免費獲取StockNews.com關於Imago BioSciences(IMGO)的研究報告
- 請真正的Palantir站起來好嗎？
- 只因為買了一件非常誘人的東西就買了腳鎖
- Ocugen或Amarin是值得購買的便士股票嗎？
- 這兩家金融科技公司是在第二季度盈利後買入的嗎？
- Chipotle正在醖釀另一輪2000美元的漲勢
Receive News & Ratings for Imago BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imago BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.
接受Imago生物科學日報的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Imago BioSciences和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧